As M&A buzz heats up, Parex­el plans 1,200 lay­offs; Grü­nen­thal is hir­ing for its new Boston/Cam­bridge cen­ter

→ As ru­mors of a po­ten­tial buy­out spread fol­low­ing a move to cut pro­ject­ed rev­enue, the big CRO Parex­el is lay­ing the ground­work for a ma­jor cut in staff. In a fil­ing with the SEC on May 4, the Waltham, MA-based com­pa­ny out­lined plans to slash up to 1,200 jobs at the glob­al clin­i­cal tri­al op­er­a­tion — far more than the 400 job cuts that had been in the works. The Boston Busi­ness Jour­nal re­port­ed that sto­ry first. The Wall Street Jour­nal, mean­while, re­port­ed ear­li­er in the week that Parex­el has be­gun work­ing with in­vest­ment bankers to beat the bush­es for a po­ten­tial buy­er, con­tin­u­ing a decade-long con­sol­i­da­tion in the CRO busi­ness.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER